Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1,385,805 |
|
|||||
| News | (1) | ||||||
| Day High | 2.15 | Low High |
|||||
| Day Low | 1.96 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Coherus BioSciences Inc | CHRS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.09 | 4.59% | 2.05 | 18:54:46 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.97 | 1.96 | 2.15 | 2.06 | 1.96 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,460 | 1,385,805 | US$ 2.02 | US$ 2,805,497 | - | 1.4301 - 8.22 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:56:53 | 65 | US$ 2.04 | USD |
Coherus BioSciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 229.41M | 111.36M | - | 257.24M | -237.89M | -2.14 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Coherus BioSciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.19 | 2.2101 | 1.91 | 1.99 | 1,239,485 | -0.14 | -6.39% |
| 1 Month | 2.34 | 2.61 | 1.91 | 2.22 | 1,623,481 | -0.29 | -12.39% |
| 3 Months | 2.29 | 2.87 | 1.91 | 2.36 | 2,417,402 | -0.24 | -10.48% |
| 6 Months | 3.30 | 3.73 | 1.4301 | 2.46 | 4,741,847 | -1.25 | -37.88% |
| 1 Year | 7.49 | 8.22 | 1.4301 | 3.27 | 4,069,556 | -5.44 | -72.63% |
| 3 Years | 14.92 | 19.32 | 1.4301 | 5.62 | 1,971,984 | -12.87 | -86.26% |
| 5 Years | 16.00 | 23.91 | 1.4301 | 9.12 | 1,631,084 | -13.95 | -87.19% |
Coherus BioSciences Description
| Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. |
